Cargando…

Possible EU futures for CRISPR-edited plants: Little margin for optimism?

This article addresses the scenarios that may be encountered by the first application for pre-market approval of a CRISPR-edited plant in the EU. Two alternative scenarios are considered in the short and medium term. One of these possible EU futures depends on the final drafting and approval of EU l...

Descripción completa

Detalles Bibliográficos
Autores principales: Escajedo San-Epifanio, Leire, Filibi, Igor, Lasa López, Ainhoa, Puigdomènech, Pere, Uncetabarrenechea Larrabe, Javier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10061071/
https://www.ncbi.nlm.nih.gov/pubmed/37008488
http://dx.doi.org/10.3389/fpls.2023.1141455
_version_ 1785017218391605248
author Escajedo San-Epifanio, Leire
Filibi, Igor
Lasa López, Ainhoa
Puigdomènech, Pere
Uncetabarrenechea Larrabe, Javier
author_facet Escajedo San-Epifanio, Leire
Filibi, Igor
Lasa López, Ainhoa
Puigdomènech, Pere
Uncetabarrenechea Larrabe, Javier
author_sort Escajedo San-Epifanio, Leire
collection PubMed
description This article addresses the scenarios that may be encountered by the first application for pre-market approval of a CRISPR-edited plant in the EU. Two alternative scenarios are considered in the short and medium term. One of these possible EU futures depends on the final drafting and approval of EU legislation on certain New Genomic Techniques, which was started in 2021 and is due to be quite advanced before the next European Parliament elections in 2024. Since the proposed legislation excludes plants with foreign DNA, two different approval processes for CRISPR-edited plants will coexist if the legislation enters into force: one for plants whose genome has been altered, resulting in mutagenesis, cisgenesis and intragenesis; and the second for plants whose alterations result in transgenesis in general. In the event that this legislative process does not succeed, CRISPR-edited plants in the EU could face a regulatory scenario whose foundations were laid in the 1990s: the regulatory framework that applies to GM crops, food and feed. In this review, an ad hoc analytical framework has been built that considers in depth the two possible futures for CRISPR-edited plants in the EU. This framework emphasises the way in which the European Union and the Member States (MS), with their respective national interests, have historically shaped the regulatory framework for plant breeding in the EU. On the basis of the analyses carried out on the two possible futures for CRISPR-edited plants and of their potential with respect to plant breeding, the main conclusions are the following. Firstly, that the regulatory review that started in 2021 is not in itself “good enough” for plant breeding and CRISPR-edited plants. Secondly, that compared to its alternative, the regulatory review currently underway contains at least some promising improvements in the short term. Hence, thirdly, in addition to adopting the current regulation, the MS need to continue to work towards a substantial improvement in the legal status of plant breeding in the EU in the medium term.
format Online
Article
Text
id pubmed-10061071
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-100610712023-03-31 Possible EU futures for CRISPR-edited plants: Little margin for optimism? Escajedo San-Epifanio, Leire Filibi, Igor Lasa López, Ainhoa Puigdomènech, Pere Uncetabarrenechea Larrabe, Javier Front Plant Sci Plant Science This article addresses the scenarios that may be encountered by the first application for pre-market approval of a CRISPR-edited plant in the EU. Two alternative scenarios are considered in the short and medium term. One of these possible EU futures depends on the final drafting and approval of EU legislation on certain New Genomic Techniques, which was started in 2021 and is due to be quite advanced before the next European Parliament elections in 2024. Since the proposed legislation excludes plants with foreign DNA, two different approval processes for CRISPR-edited plants will coexist if the legislation enters into force: one for plants whose genome has been altered, resulting in mutagenesis, cisgenesis and intragenesis; and the second for plants whose alterations result in transgenesis in general. In the event that this legislative process does not succeed, CRISPR-edited plants in the EU could face a regulatory scenario whose foundations were laid in the 1990s: the regulatory framework that applies to GM crops, food and feed. In this review, an ad hoc analytical framework has been built that considers in depth the two possible futures for CRISPR-edited plants in the EU. This framework emphasises the way in which the European Union and the Member States (MS), with their respective national interests, have historically shaped the regulatory framework for plant breeding in the EU. On the basis of the analyses carried out on the two possible futures for CRISPR-edited plants and of their potential with respect to plant breeding, the main conclusions are the following. Firstly, that the regulatory review that started in 2021 is not in itself “good enough” for plant breeding and CRISPR-edited plants. Secondly, that compared to its alternative, the regulatory review currently underway contains at least some promising improvements in the short term. Hence, thirdly, in addition to adopting the current regulation, the MS need to continue to work towards a substantial improvement in the legal status of plant breeding in the EU in the medium term. Frontiers Media S.A. 2023-03-16 /pmc/articles/PMC10061071/ /pubmed/37008488 http://dx.doi.org/10.3389/fpls.2023.1141455 Text en Copyright © 2023 Escajedo San-Epifanio, Filibi, Lasa López, Puigdomènech and Uncetabarrenechea Larrabe https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Plant Science
Escajedo San-Epifanio, Leire
Filibi, Igor
Lasa López, Ainhoa
Puigdomènech, Pere
Uncetabarrenechea Larrabe, Javier
Possible EU futures for CRISPR-edited plants: Little margin for optimism?
title Possible EU futures for CRISPR-edited plants: Little margin for optimism?
title_full Possible EU futures for CRISPR-edited plants: Little margin for optimism?
title_fullStr Possible EU futures for CRISPR-edited plants: Little margin for optimism?
title_full_unstemmed Possible EU futures for CRISPR-edited plants: Little margin for optimism?
title_short Possible EU futures for CRISPR-edited plants: Little margin for optimism?
title_sort possible eu futures for crispr-edited plants: little margin for optimism?
topic Plant Science
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10061071/
https://www.ncbi.nlm.nih.gov/pubmed/37008488
http://dx.doi.org/10.3389/fpls.2023.1141455
work_keys_str_mv AT escajedosanepifanioleire possibleeufuturesforcrispreditedplantslittlemarginforoptimism
AT filibiigor possibleeufuturesforcrispreditedplantslittlemarginforoptimism
AT lasalopezainhoa possibleeufuturesforcrispreditedplantslittlemarginforoptimism
AT puigdomenechpere possibleeufuturesforcrispreditedplantslittlemarginforoptimism
AT uncetabarrenechealarrabejavier possibleeufuturesforcrispreditedplantslittlemarginforoptimism